Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05909358 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Solidarity/Tokomeza Ebola Trial

Study acronym: TOKOMEZA
StatusNot Yet Recruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
The TokomezaPlus Ebola trial is a phase I/II double blind randomised clinical trial designed to assess the safety and immunogenicity of candidate SUDV vaccines in Uganda during the inter outbreak period. Uganda is prone to Ebola virus disease outbreaks especially those caused by the Ebola Sudan (SUDV) species. TokomezaPlus Ebola Vaccine trial protocol has two main components: a) Safety b) Immunogenicity and is designed to create a living protocol that will be used to study the safety and immunogenicity of SUDV-candidate vaccines in the East African EVD-prone countries.
Trial Details
NCT Number NCT05909358
Lead Sponsor Makerere University
Collaborators: Makerere University Lung Institute, MRC/UVRI and LSHTM Uganda Research Unit, Makerere University Walter Reed Program, Epicentre, Uganda Virus Research Institute-International Aids Vaccine Initiative, Ministry of Health, Uganda
Conditions
(from sponsor)		 Sudan Ebola Virus Vaccines
Enrollment 2,121 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov